Hologic on Jan. 14 priced and allocated the cross-border seven-year term loan backing its Blackstone- and TPG Capital-led buyout, split between a $7.25 billion tranche at S+225 offered at 99.75, and a €1.3 billion piece at E+275 offered at 100. Citi was left-lead arranger on the dollars. BofA Securities and Barclays were left-lead arrangers on the euros.
The dollars feature one margin step-down of 25 bps at 5.55x first-lien net leverage, while there are two step-downs of 25 bps each on the euros at 5.8x and 5.55x leverage. Both also include a 25 bps step-down upon an IPO.
Final terms on both tranches are tight of talk. At launch on a Jan. 6 call, the deal was guided as a $7 billion-equivalent facility split between a $5 billion tranche in dollars and $2 billion-equivalent in euros, guided at S+275-300 and E+300-325 respectively, both offered at 99.50. Replies were accelerated by a day at the end of last week, and terms were then revised on Jan. 14 to a $7 billion tranche on the dollars and $1.5 billion on the euros, guided at S+225-250/99.75 and E+275/100, respectively. Final terms then followed, including a further upsize on the dollars. The upsized dollar tranche supported a reduction in the term loan A, which now stands at $1.25 billion, and a privately placed second-lien loan totaling $1.5 billion. A $750 million revolver rounds out the debt.
At final terms, the yields to maturity work out to 6.09% for the dollar tranche and 4.86% for the euro tranche. Per the initial talk at launch, the yields were 6.67-6.93% and 5.20-5.46%, respectively. The euro tranche is the tightest print for a debut sponsor-backed buyout since an €845 million loan backing the TDR and Issa brothers’ buyout of Asda closed in 2021 at E+275.
Lenders are offered six months of 101 soft call protection, and there is 100 bps of MFN protection with a six-month sunset. Documents were amended in syndication, including the removal of the high water marking concept and an increase in all references to the first-lien net leverage ratio in covenants by 0.3x, based on the increase in the closing date first-lien net leverage.
RBC, SMBC, Deutsche Bank, HSBC, MUFG, Natixis, Societe Generale, Truist Securities, UBS and Wells Fargo were joint arrangers. Citi was agent.
Hologic, based in Marlborough, Mass., is a medical technology company providing diagnostics products, medical imaging systems and surgical products focused on women’s health.
Ratings are B+/B1 (issuer) and B+/Ba3 (issue), with a 3 recovery rating and a stable outlook on both. Hopper Merger Sub Inc. is the borrower.
Proceeds from the deal will be used to partially finance the acquisition of Hologic by Blackstone and TPG in a transaction with an enterprise value of up to $17.9 billion. The deal will also include minority investments from ADIA and GIC. Closing is expected in the first half of 2026, subject to shareholder and regulatory approvals.
In their assessments, agencies noted Hologic’s scale and leading market positions in its core areas, as well as revenue diversity across products and customers. In its assessment, Moody’s noted leverage was high, though said it expects the multiple to fall over the next 12-19 months on earnings growth and debt repayments. S&P also expects improving revenue trends, noting planned cost savings as well as solid operating fundamentals and long-term prospects. Hologic faces strong competitive pressure from well-capitalized and larger rivals and has some geographic concentration in the US, which is responsible for 74% of revenues, agencies add.
Featured image by Utah778/Getty Images
Learn about our editorial standards.